搜索结果：Dermatology (Basel, Switzerland)

Imatinib mesylate (STI 571; Gleevec; Novartis Pharmaceuticals, Basel, Switzerland) is an orally available tyrosine kinase inhibitor that targets a constitutively activated BCR-ABL tyrosine kinase with additional inhibitory effects on platelet derived growth factor (PDGF) receptors alpha and beta, and KIT. It has revolutionized the treatment of adult and pediatric patients with Philadelphia chromosome positive chronic myelogenous leukemia (CML) and is also FDA-approved for KIT-positive advanced gastrointestinal tumor (GIST) and dermatofibrosarcoma protuberans. A wide spectrum of dermatologic toxicities has been associated with this agent, among which a maculopapular rash is the most common event. In addition, a variety of pigmentary abnormalities of the skin and mucosal surfaces have been reported. Hypopigmentation is a well-recognized adverse effect. In contrast, paradoxical hyperpigmentation has only rarely been documented. In this case report we describe imatinib-induced cutaneous hyperpigmentation and graying of hair occurring in the same patient with dermatofibrosarcoma protuberans treated with imatinib.

Dermatologic TherapyVolume 33, Issue 4 e13774 Letter Virtual conferences of dermatology during the COVID-19 pandemic Mohamad Goldust, Mohamad Goldust orcid.org/0000-0002-9615-1246 Department of Dermatology and Allergy, University Hospital Basel, Basel, SwitzerlandSearch for more papers by this authorSwathi Shivakumar, Swathi Shivakumar orcid.org/0000-0002-4497-7687 Consultant Dermatologist, Cosmetiq Clinic, Thiruvananthapuram, Kerala, IndiaSearch for more papers by this authorGeorge Kroumpouzos, George Kroumpouzos Department of Dermatology, Alpert Medical School of Brown University, Providence, Rhode Island, USA Department of Dermatology, Medical School of Jundiaí, São Paulo, BrazilSearch for more papers by this authorDedee F. Murrell, Dedee F. Murrell Department of Dermatology, St George Hospital, Faculty of Medicine, University of New South Wales, Sydney, AustraliaSearch for more papers by this authorLidia Rudnicka, Lidia Rudnicka orcid.org/0000-0002-8308-1023 Department of Dermatology, Medical University of Warsaw, Warsaw, PolandSearch for more papers by this authorMohammad Jafferany, Mohammad Jafferany orcid.org/0000-0001-6358-9068 College of Medicine, Central Michigan University, Saginaw, MI, USASearch for more papers by this authorAlexander A. Navarini, Corresponding Author Alexander A. Navarini [email protected] Department of Dermatology and Allergy, University Hospital Basel, Basel, Switzerland Correspondence Alexander A. Navarini, Department of Dermatology and Allergy, University Hospital of Basel, Basel, Switzerland. Email: [email protected]Search for more papers by this author Mohamad Goldust, Mohamad Goldust orcid.org/0000-0002-9615-1246 Department of Dermatology and Allergy, University Hospital Basel, Basel, SwitzerlandSearch for more papers by this authorSwathi Shivakumar, Swathi Shivakumar orcid.org/0000-0002-4497-7687 Consultant Dermatologist, Cosmetiq Clinic, Thiruvananthapuram, Kerala, IndiaSearch for more papers by this authorGeorge Kroumpouzos, George Kroumpouzos Department of Dermatology, Alpert Medical School of Brown University, Providence, Rhode Island, USA Department of Dermatology, Medical School of Jundiaí, São Paulo, BrazilSearch for more papers by this authorDedee F. Murrell, Dedee F. Murrell Department of Dermatology, St George Hospital, Faculty of Medicine, University of New South Wales, Sydney, AustraliaSearch for more papers by this authorLidia Rudnicka, Lidia Rudnicka orcid.org/0000-0002-8308-1023 Department of Dermatology, Medical University of Warsaw, Warsaw, PolandSearch for more papers by this authorMohammad Jafferany, Mohammad Jafferany orcid.org/0000-0001-6358-9068 College of Medicine, Central Michigan University, Saginaw, MI, USASearch for more papers by this authorAlexander A. Navarini, Corresponding Author Alexander A. Navarini [email protected] Department of Dermatology and Allergy, University Hospital Basel, Basel, Switzerland Correspondence Alexander A. Navarini, Department of Dermatology and Allergy, University Hospital of Basel, Basel, Switzerland. Email: [email protected]Search for more papers by this author First published: 07 June 2020 https://doi.org/10.1111/dth.13774Citations: 2Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article.Citing Literature Volume33, Issue4July/August 2020e13774 RelatedInformation

This paper provides an overview of artificial-intelligence (AI), as applied to dermatology. We focus our discussion on methodology, AI applications for various skin diseases, limitations, and future opportunities. We review how the current image-based models are being implemented in dermatology across disease subsets, and highlight the challenges facing widespread adoption. Additionally, we discuss how the future of AI in dermatology might evolve and the emerging paradigm of large language, and multi-modal models to emphasize the importance of developing responsible, fair, and equitable models in dermatology.

Dermatologic TherapyVolume 33, Issue 4 e13343 Letter Learning from history: Coronavirus outbreaks in the past Pooja Arora, Pooja Arora orcid.org/0000-0002-0718-6990 Department of Dermatology, PGIMER and Dr Ram Manohar Lohia Hospital, New Delhi, IndiaSearch for more papers by this authorMohammad Jafferany, Mohammad Jafferany orcid.org/0000-0001-6358-9068 College of Medicine, Central Michigan University, Saginaw, Michigan, USASearch for more papers by this authorTorello Lotti, Torello Lotti orcid.org/0000-0003-0840-1936 Department of Dermatology, University of Studies Guglielmo Marconi, Rome, ItalySearch for more papers by this authorRoxanna Sadoughifar, Roxanna Sadoughifar Department of Dermatology, University of Rome G. Marconi, Rome, Italy Bidarskincenter, Tehran, IranSearch for more papers by this authorMohamad Goldust, Corresponding Author Mohamad Goldust [email protected] [email protected] orcid.org/0000-0002-9615-1246 Department of Dermatology, University of Rome G. Marconi, Rome, Italy Department of Dermatology, University Medical Center Mainz, Mainz, Germany Department of Dermatology, University Hospital Basel, Basel, Switzerland Correspondence Mohamad Goldust, Department of Dermatology, University Medical Center Mainz, Mainz, Germany. Email: [email protected]Search for more papers by this author Pooja Arora, Pooja Arora orcid.org/0000-0002-0718-6990 Department of Dermatology, PGIMER and Dr Ram Manohar Lohia Hospital, New Delhi, IndiaSearch for more papers by this authorMohammad Jafferany, Mohammad Jafferany orcid.org/0000-0001-6358-9068 College of Medicine, Central Michigan University, Saginaw, Michigan, USASearch for more papers by this authorTorello Lotti, Torello Lotti orcid.org/0000-0003-0840-1936 Department of Dermatology, University of Studies Guglielmo Marconi, Rome, ItalySearch for more papers by this authorRoxanna Sadoughifar, Roxanna Sadoughifar Department of Dermatology, University of Rome G. Marconi, Rome, Italy Bidarskincenter, Tehran, IranSearch for more papers by this authorMohamad Goldust, Corresponding Author Mohamad Goldust [email protected] [email protected] orcid.org/0000-0002-9615-1246 Department of Dermatology, University of Rome G. Marconi, Rome, Italy Department of Dermatology, University Medical Center Mainz, Mainz, Germany Department of Dermatology, University Hospital Basel, Basel, Switzerland Correspondence Mohamad Goldust, Department of Dermatology, University Medical Center Mainz, Mainz, Germany. Email: [email protected]Search for more papers by this author First published: 28 March 2020 https://doi.org/10.1111/dth.13343Citations: 11Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article.Citing Literature Volume33, Issue4July/August 2020e13343 This article also appears in:Dermatologic Therapy COVID-19 Articles RelatedInformation

Dermatologic TherapyVolume 33, Issue 4 e13339 Letter COVID-19 in the pediatric population Ayman Abdelmaksoud, Ayman Abdelmaksoud orcid.org/0000-0003-4848-959X Mansoura Dermatology, Venerology and Leprology Hospital, Mansoura, EgyptSearch for more papers by this authorGeorge Kroumpouzos, George Kroumpouzos Department of Dermatology, Alpert Medical School of Brown University, Providence, Rhode Island Department of Dermatology, Medical School of Jundiaí, São Paulo, BrazilSearch for more papers by this authorMohammad Jafferany, Mohammad Jafferany orcid.org/0000-0001-6358-9068 College of Medicine, Central Michigan University, Saginaw, Michigan, USASearch for more papers by this authorTorello Lotti, Torello Lotti orcid.org/0000-0003-0840-1936 University of Studies Guglielmo Marconi, Rome, ItalySearch for more papers by this authorRoxanna Sadoughifar, Roxanna Sadoughifar Bidarskincenter, Tehran, Iran University of Rome G. Marconi, Rome, ItalySearch for more papers by this authorMohamad Goldust, Corresponding Author Mohamad Goldust [email protected] orcid.org/0000-0002-9615-1246 Department of Dermatology, University Medical Center Mainz, Mainz, Germany Department of Dermatology, University Hospital Basel, Basel, Switzerland Correspondence Mohamad Goldust, Department of Dermatology, University Medical Center Mainz, Mainz,Germany. Email: [email protected]Search for more papers by this author Ayman Abdelmaksoud, Ayman Abdelmaksoud orcid.org/0000-0003-4848-959X Mansoura Dermatology, Venerology and Leprology Hospital, Mansoura, EgyptSearch for more papers by this authorGeorge Kroumpouzos, George Kroumpouzos Department of Dermatology, Alpert Medical School of Brown University, Providence, Rhode Island Department of Dermatology, Medical School of Jundiaí, São Paulo, BrazilSearch for more papers by this authorMohammad Jafferany, Mohammad Jafferany orcid.org/0000-0001-6358-9068 College of Medicine, Central Michigan University, Saginaw, Michigan, USASearch for more papers by this authorTorello Lotti, Torello Lotti orcid.org/0000-0003-0840-1936 University of Studies Guglielmo Marconi, Rome, ItalySearch for more papers by this authorRoxanna Sadoughifar, Roxanna Sadoughifar Bidarskincenter, Tehran, Iran University of Rome G. Marconi, Rome, ItalySearch for more papers by this authorMohamad Goldust, Corresponding Author Mohamad Goldust [email protected] orcid.org/0000-0002-9615-1246 Department of Dermatology, University Medical Center Mainz, Mainz, Germany Department of Dermatology, University Hospital Basel, Basel, Switzerland Correspondence Mohamad Goldust, Department of Dermatology, University Medical Center Mainz, Mainz,Germany. Email: [email protected]Search for more papers by this author First published: 27 March 2020 https://doi.org/10.1111/dth.13339Citations: 8Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article.Citing Literature Volume33, Issue4July/August 2020e13339 This article also appears in:Dermatologic Therapy COVID-19 Articles RelatedInformation

Conflicts of interest exist in dermatology when professional judgement concerning a primary interest, such as research validity, may be influenced by a secondary interest, such as financial gain from a for-profit organization. Conflict of interest is a condition and not a behaviour, although there is clear evidence that gifts influence behaviour. Little has been written about conflicts of interest in dermatology. This series of papers raises awareness of the subject by exploring it in greater depth from the perspective of a dermatology researcher, an industry researcher, a dermatology journal editor, a health services researcher and a patient representative. Collectively, they illustrate the many ways in which conflicts can pervade the world of dermatology publications and patient support group activities.

In photodynamic therapy (PDT) a photosensitizer - a molecule that is activated by light - is administered and exposed to a light source. This leads both to destruction of cells targeted by the particular type of photosensitizer, and immunomodulation. Given the ease with which photosensitizers and light can be delivered to the skin, it should come as no surprise that PDT is an increasingly utilized therapeutic in dermatology. PDT is used commonly to treat precancerous cells, sun-damaged skin, and acne. It has reportedly also been used to treat other conditions including inflammatory disorders and cutaneous infections. This review discusses the principles behind how PDT is used in dermatology, as well as evidence for current applications of PDT.

OBJECTIVE: In dermatology, patient and physician adoption of light-emitting diode (LED) medical technology continues to grow as research indicates that LEDs may be used to treat skin conditions. The goal of this systematic review is to critically analyze published randomized controlled trials (RCTs) and provide evidence-based recommendations on the therapeutic uses of LEDs in dermatology based on published efficacy and safety data. METHODS: A systematic review of the published literature on the use of LED treatments for skin conditions was performed on September 13th 2017. RESULTS: Thirty-one original RCTs were suitable for review. CONCLUSIONS: LEDs represent an emerging modality to alter skin biology and change the paradigm of managing skin conditions. Acne vulgaris, herpes simplex and zoster, and acute wound healing received grade of recommendation B. Other skin conditions received grade of recommendation C or D. Limitations of some studies include small patient sample sizes (n < 20), absent blinding, no sham placebo, and varied treatment parameters. Due to few incidences of adverse events, affordability, and encouraging clinical results, we recommend that physicians use LEDs in clinical practice and researchers continue to explore the use of LEDs to treat skin conditions. Lasers Surg. Med. 9999:1-16, 2018. © 2018 The Authors. Lasers in Surgery and Medicine Published by Wiley Periodicals, Inc.

The problem of antimicrobial resistance is increasingly present and requires the discovery of new antimicrobial agents. Although the healing features of silver have been recognized since ancient times, silver has not been used due to newly discovered antibiotics. Thanks to technology development, a significant step forward has been made in silver nanoparticles research. Nowadays, silver nanoparticles are a frequent target of researchers to find new and better drugs. Namely, there is a need for silver nanoparticles as alternative antibacterial nanobiotics. Silver nanoparticles (AgNPs), depending on their size and shape, also have different antimicrobial activity. In addition to their apparent antibacterial activity, AgNPs can serve as drug delivery systems and have anti-thrombogenic, anti-platelet, and anti-hypertensive properties. Today they are increasingly used in clinical medicine and dental medicine. This paper presents silver antimicrobial activity and its use in dentistry, cardiology, and dermatology, where it has an extensive range of effects.

In addition to the print version, an electronic version, as well as electronic access to individual chapters, is offered to meet the needs of international readers.

BACKGROUND: Urgent consultations for skin disorders are commonly done in different settings. Scarce data exist about the characteristics of these patients. OBJECTIVE: The aim of this study was to analyse specific characteristics of patients receiving an urgent consultation at a dermatology department in a university hospital. METHODS: We prospectively recorded the data of all patients having had an urgent consultation during a period of 12 months. RESULTS: We registered 2,222 urgent consultations. The most frequent diagnoses were eczemas (24.8%), dermatomycoses (5.1%) and dermatitis not otherwise specified (4.8%). The most frequent treatments were topical steroids, emollients, topical antibiotics, systemic antihistamines, antibiotics and virostatics. 2.2% of patients were hospitalized, 78.8% asked for a consultation for a disease lasting less than 4 weeks, and 6.9% presented the same day as the skin disease appeared. CONCLUSIONS: This study shows the characteristics of patients receiving an urgent dermatologic consultation. It underlines the need for collaboration between dermatologists, other physicians, general practitioners and nurses.

暂无摘要（点击查看原文获取完整内容）

The CO(2) laser has been used extensively in dermatological surgery over the past 30 years and is now recognised as the gold standard for soft tissue vaporization. Considering that the continuous wave CO(2) laser delivery system and the newer "superpulsed" and scanned CO(2) systems have progressively changed our practice and patient satisfaction, a long range documentation can be useful. Our experience has demonstrated that the use of CO(2) laser involves a reduced healing time, an infrequent need for anaesthesia, reduced thermal damage, less bleeding, less inflammation, the possibility of intra-operative histologic and/or cytologic examination, and easy access to anatomically difficult areas. Immediate side effects have been pain, erythema, edema, typically see with older methods, using higher power. The percentage of after-treatment keloids and hypertrophic scars observed was very low (~1%) especially upon the usage of lower parameters. The recurrence of viral lesions (condylomas and warts) have been not more frequent than those due to other techniques. Tumor recurrence is minor compared with radiotherapy or surgery. This method is a valid alternative to surgery and/or diathermocoagulation for microsurgery of soft tissues. Our results are at times not consistent with those published in the literature, stressing the concept that multicentric studies that harmonization methodology and the patient selection are vital.

Plasma medicine has become an emerging field in medical sciences since cold plasma has demonstrated significant antibacterial properties in vitro and in vivo. However, systematic antimicrobial plasma testing against bacteria, fungi, and parasites is still lacking. Chronic wounds, fungal skin and nail infections, and colonization with multidrug-resistant pathogens like Staphylococcus aureus (MRSA) often pose significant therapeutic and economical problems and new therapeutic concepts are strongly warranted. The challenge of worldwide increasing resistance problems including different pathogens like methicillin-resistant MRSA, vancomycin-resistant enterococci, and gram-negative species producing betalactam hydrolysing enzymes (extended spectrum -lactamases) constitute the need for alternative antimicrobial treatments. Cold plasma therapy with a completely different mode of action compared to conventional antimicrobials may offer an alternative to conventional external antibiotic and antiseptic therapies. In order to estimate the possible role as physical antiseptic, basic susceptibility data from plasma are needed. To provide such data, the plasma susceptibility of representative skin and wound pathogens against low-temperature atmospheric pressure plasma jet (APPJ device) and dielectric barrier discharge plasma treatment was tested in vitro on agar. The same plasma sources were used to test clinical fungal isolates in vitro and isolates of the parasite demodex folliculorum ex vivo. Plasma treatment proved to be highly effective in eradicating all treated strains and species including Escherichia coli, Pseudomonas aeruginosa, Klebsiella group (K. pneumoniae ssp. pneumoniae, K. oxytoca), Staphylococcus aureus, hemolysing Lancefield Streptococci (group A and B), Proteus group (P. mirabilis, P. vulgaris), Acinetobacter spp., Stenotrophomonas spp., Enterococcus faecalis, Candida albicans, and Staphylococcus epidermidis. Plasma irradiation of Trichophyton rubrum, Trichophyton interdigitale, Microsporon canis, and the yeast Candida albicans was able to kill >90% of the organisms during 30 s in vitro with no isolate exhibiting resistance. The APPJ-plasma killed Demodex folliculorum after exposure time of 2 s. Our data suggest plasma as a possible new option in the treatment of microbial, fungal, and parasitic dermal infections.

Peptides are central to the regulation and modulation of the chemical reactions and biological responses that occur in nature. Many physiological processes are affected by the interactions of these peptides, including cell proliferation and migration, inflammation, melanogenesis, angiogenesis and innate immunity. Thus, biologically active peptides offer a great potential medically and therapeutically. Moreover, the ability to generate synthetic peptides with attention to specifically modulating their pharmacokinetics and properties for increased potency, delivery and stability has spurred much interest in this rapidly growing field of research. In this review, we focus on the therapeutic uses of bioactive peptides as antimicrobials and effectors of neurotransmitter release. We also highlight the advantages and challenges associated with this new technology and discuss methods for improving oligopeptide transdermal delivery.

The panendemic of HIV has markedly influenced the dermatology of our generation. This new infection produced atypical manifestations of known dermatological diseases. And beyond that, mucocutaneous diseases emerged, which had not yet been described. Classical epidemiological studies concluded that clustering of AIDS cases could be explained only if AIDS was an infection transmitted by sexual activity or blood. Switzerland was hit early on by the HIV epidemic, and Theo Rufli, the leading expert on sexually transmitted diseases in our country, was involved from the beginning. He contributed with his team to a better delineation of the cutaneous manifestations of HIV infection by directing one of the largest prospective studies on the natural course of cutaneous manifestations of HIV. In addition, he participated in studies which documented new skin diseases in HIV-infected patients. From the very beginning of the epidemic in Switzerland, Theo Rufli founded an organization which helped patients cope with their diagnosis. In Basel, an anonymous consultation facility was established. Theo Rufli also strongly supported the 'Stop AIDS' campaign. This review looks back on the history of HIV in Switzerland and especially in Basel.

暂无摘要（点击查看原文获取完整内容）

BACKGROUND: Detailed, comprehensive, and timely reporting on population health by underlying causes of disability and premature death is crucial to understanding and responding to complex patterns of disease and injury burden over time and across age groups, sexes, and locations. The availability of disease burden estimates can promote evidence-based interventions that enable public health researchers, policy makers, and other professionals to implement strategies that can mitigate diseases. It can also facilitate more rigorous monitoring of progress towards national and international health targets, such as the Sustainable Development Goals. For three decades, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has filled that need. A global network of collaborators contributed to the production of GBD 2021 by providing, reviewing, and analysing all available data. GBD estimates are updated routinely with additional data and refined analytical methods. GBD 2021 presents, for the first time, estimates of health loss due to the COVID-19 pandemic. METHODS: The GBD 2021 disease and injury burden analysis estimated years lived with disability (YLDs), years of life lost (YLLs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries using 100 983 data sources. Data were extracted from vital registration systems, verbal autopsies, censuses, household surveys, disease-specific registries, health service contact data, and other sources. YLDs were calculated by multiplying cause-age-sex-location-year-specific prevalence of sequelae by their respective disability weights, for each disease and injury. YLLs were calculated by multiplying cause-age-sex-location-year-specific deaths by the standard life expectancy at the age that death occurred. DALYs were calculated by summing YLDs and YLLs. HALE estimates were produced using YLDs per capita and age-specific mortality rates by location, age, sex, year, and cause. 95% uncertainty intervals (UIs) were generated for all final estimates as the 2·5th and 97·5th percentiles values of 500 draws. Uncertainty was propagated at each step of the estimation process. Counts and age-standardised rates were calculated globally, for seven super-regions, 21 regions, 204 countries and territories (including 21 countries with subnational locations), and 811 subnational locations, from 1990 to 2021. Here we report data for 2010 to 2021 to highlight trends in disease burden over the past decade and through the first 2 years of the COVID-19 pandemic. FINDINGS: Global DALYs increased from 2·63 billion (95% UI 2·44-2·85) in 2010 to 2·88 billion (2·64-3·15) in 2021 for all causes combined. Much of this increase in the number of DALYs was due to population growth and ageing, as indicated by a decrease in global age-standardised all-cause DALY rates of 14·2% (95% UI 10·7-17·3) between 2010 and 2019. Notably, however, this decrease in rates reversed during the first 2 years of the COVID-19 pandemic, with increases in global age-standardised all-cause DALY rates since 2019 of 4·1% (1·8-6·3) in 2020 and 7·2% (4·7-10·0) in 2021. In 2021, COVID-19 was the leading cause of DALYs globally (212·0 million [198·0-234·5] DALYs), followed by ischaemic heart disease (188·3 million [176·7-198·3]), neonatal disorders (186·3 million [162·3-214·9]), and stroke (160·4 million [148·0-171·7]). However, notable health gains were seen among other leading communicable, maternal, neonatal, and nutritional (CMNN) diseases. Globally between 2010 and 2021, the age-standardised DALY rates for HIV/AIDS decreased by 47·8% (43·3-51·7) and for diarrhoeal diseases decreased by 47·0% (39·9-52·9). Non-communicable diseases contributed 1·73 billion (95% UI 1·54-1·94) DALYs in 2021, with a decrease in age-standardised DALY rates since 2010 of 6·4% (95% UI 3·5-9·5). Between 2010 and 2021, among the 25 leading Level 3 causes, age-standardised DALY rates increased most substantially for anxiety disorders (16·7% [14·0-19·8]), depressive disorders (16·4% [11·9-21·3]), and diabetes (14·0% [10·0-17·4]). Age-standardised DALY rates due to injuries decreased globally by 24·0% (20·7-27·2) between 2010 and 2021, although improvements were not uniform across locations, ages, and sexes. Globally, HALE at birth improved slightly, from 61·3 years (58·6-63·6) in 2010 to 62·2 years (59·4-64·7) in 2021. However, despite this overall increase, HALE decreased by 2·2% (1·6-2·9) between 2019 and 2021. INTERPRETATION: Putting the COVID-19 pandemic in the context of a mutually exclusive and collectively exhaustive list of causes of health loss is crucial to understanding its impact and ensuring that health funding and policy address needs at both local and global levels through cost-effective and evidence-based interventions. A global epidemiological transition remains underway. Our findings suggest that prioritising non-communicable disease prevention and treatment policies, as well as strengthening health systems, continues to be crucially important. The progress on reducing the burden of CMNN diseases must not stall; although global trends are improving, the burden of CMNN diseases remains unacceptably high. Evidence-based interventions will help save the lives of young children and mothers and improve the overall health and economic conditions of societies across the world. Governments and multilateral organisations should prioritise pandemic preparedness planning alongside efforts to reduce the burden of diseases and injuries that will strain resources in the coming decades. FUNDING: Bill & Melinda Gates Foundation.

Editorials| October 08 2009 Classification of Autosomal Dominant Palmoplantar Keratoderma: Past – Present – Future Subject Area: Dermatology , Immunology and Allergy P.H. Itin P.H. Itin Department of Dermatology, University of Basel, Switzerland Search for other works by this author on: This Site PubMed Google Scholar Dermatology (1992) 185 (3): 163–165. https://doi.org/10.1159/000247439 Article history Published Online: October 08 2009 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation P.H. Itin; Classification of Autosomal Dominant Palmoplantar Keratoderma: Past – Present – Future. Dermatology 1 March 1992; 185 (3): 163–165. https://doi.org/10.1159/000247439 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsDermatology Search Advanced Search Article PDF first page preview Close Modal This content is only available via PDF. 1992Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. You do not currently have access to this content.